Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marizyme Inc. MRZM

Healthcare Biotechnology
Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the development and commercialization of medical technologies that improves patient health outcomes. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure... see more

Recent & Breaking News (OTCQB:MRZM)

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM)

GlobeNewswire April 16, 2024

Marizyme CEO Delivers Business Update

GlobeNewswire October 23, 2023

Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft(TM)

GlobeNewswire October 6, 2023

Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products

GlobeNewswire May 10, 2023

Marizyme CEO Delivers Business Update

GlobeNewswire May 3, 2023

Statera Biopharma Announces Changes to Board of Directors

GlobeNewswire February 25, 2022

Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

GlobeNewswire January 5, 2022

Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing

GlobeNewswire December 23, 2021

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

GlobeNewswire December 3, 2021

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

GlobeNewswire December 3, 2021

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

GlobeNewswire November 16, 2021

Marizyme, Inc. Issues Letter to Shareholders

PR Newswire March 31, 2021

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

PR Newswire March 4, 2021

Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board

PR Newswire February 4, 2021

Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems

PR Newswire February 1, 2021

Marizyme Announces Approval for DuraGraft® in India

PR Newswire January 14, 2021

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

PR Newswire January 11, 2021

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

PR Newswire January 7, 2021

Marizyme, Inc. Expands Executive Team, Board of Directors

PR Newswire December 4, 2020

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

PR Newswire November 6, 2020